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Abstract
The extracellular signal-regulated kinases (ERK1 and 2) are widely-expressed and they modulate proliferation, survival,
differentiation, and protein synthesis in multiple cell lineages. Altered ERK1/2 signaling is found in several genetic diseases
with skeletal phenotypes, including Noonan syndrome, Neurofibromatosis type 1, and Cardio-facio-cutaneous syndrome,
suggesting that MEK-ERK signals regulate human skeletal development. Here, we examine the consequence of Erk1 and
Erk2 disruption in multiple functions of osteoclasts, specialized macrophage/monocyte lineage-derived cells that resorb
bone. We demonstrate that Erk1 positively regulates osteoclast development and bone resorptive activity, as genetic
disruption of Erk1 reduced osteoclast progenitor cell numbers, compromised pit formation, and diminished M-CSF-
mediated adhesion and migration. Moreover, WT mice reconstituted long-term with Erk1
2/2 bone marrow mononuclear
cells (BMMNCs) demonstrated increased bone mineral density as compared to recipients transplanted with WT and Erk2
2/2
BMMNCs, implicating marrow autonomous, Erk1-dependent osteoclast function. These data demonstrate Erk1 plays an
important role in osteoclast functions while providing rationale for the development of Erk1-specific inhibitors for
experimental investigation and/or therapeutic modulation of aberrant osteoclast function.
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Introduction
Normal bone physiology, as well as bone repair following injury,
depends upon the productive and destructive interactions between
osteoblasts and osteoclasts, whereby osteoblast-mediated bone
production repairs localized defects created by osteoclasts. Many
skeletal diseases result from an imbalance between osteoclast and
osteoblast numbers and/or function [1]. Generally, increased
osteoblast numbers and/or functions lead to abnormal bone
mineralization while increased osteoclast numbers and/or func-
tions underlie osteoporotic conditions. Multinucleated osteoclasts
are continuously formed from the monocyte/macrophage lineage
of hematopoietic cells [2,3], and osteoclastogenesis and normal
osteoclast function depend upon multiple cytokines and growth
factors, including macrophage colony stimulating factor (M-CSF),
receptor activator for nuclear factor kappa-B ligand (RANKL),
and transforming growth factor beta (TGFb) [4,5,6]. These factors
near-ubiquitously induce phosphorylation of Erk1 and Erk2
[4,5,6]. Intriguingly, alterations in the MAPK/ERK1/2 cascade
contribute to cardio-facio-cutaneous syndrome (CFC), Noonan
syndrome, LEOPARD syndrome, and Neurofibromatosis type 1.
These pathophysiological observations suggest roles for ERK1 and
ERK2 in human skeletal development [7,8,9].
ERK1 and ERK2 are serine/threonine-specific protein kinases
sharing 84% homology [10,11]. Upon extracellular mitogen
stimulation, the Ras-Raf-MEK cascade phosphorylates and
activates ERK1 and ERK2, which then phosphorylate cytoplas-
mic and nuclear factors that execute normal and malignant cell
functions, including gene expression, mitosis, movement, and the
regulation of apoptosis [12,13,14,15,16]. In vivo genetic studies
have shown differential and/or combined roles for Erk1 and Erk2
in multiple cell lineages, including T cells, B cells, and osteoblasts
[17,18,19,20,21,22,23]. Specifically, dual Erk1/2 disruption in
osteoblast lineages results in reduced RANKL production, leading
to a subsequent reduction in osteoclastogenesis. Likewise, studies
using pharmacologic kinase inhibitors (e.g. U0126, Wortmannin,
LY294002) have suggested the importance of these pathways to
osteoclast formation and function [24,25]. However, no genetic
study has examined Erk1 or Erk2’s direct regulation of osteoclast
physiology, although recent inquiries in other cell lineages have
discovered isoform-specific roles for Erk1 and Erk2 [7,17,23].
In the present study, we evaluated the consequence of Erk1 and
Erk2 disruption in osteoclast differentiation, migration, and bone
resorptive activity in vitro and in vivo. To accomplish these aims, we
performed functional assays on osteoclasts generated from bone
marrow progenitor cells of Erk1
2/2 and hematopoietic Erk2
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+Erk2
flox/flox) mice, and we assessed
bone mineral density in WT mice transplanted long-term with
bone marrow mononuclear cells (BMMNCs) of WT, Erk1
2/2,o r
Erk2
2/2 mice. We conclude that Erk1 plays a preponderant role
in modulating osteoclast differentiation, migration, bone resorp-
tion, and bone mineral density.
Materials and Methods
Animals
Previously described Erk1
2/2 mice and Erk2
flox/flox mice [18,22]
were crossed with Mx1Cre transgenic mice (Mx1Cre
+ Erk2
fl/fl),
allowing inducible disruption of Erk2 in all hematopoietic cells.
Cre expression was induced by intraperitoneal injections of poly I
poly C (polyIC) (300 mg at 1 mg/mL in PBS; Sigma) every two
days for a total of five injections. Genetic disruption of the Erk2
gene in Mx1Cre
+ mice was verified by PCR of the recombinant
Erk2 gene and the absence of total Erk2 protein by western blot of
mouse BMMNCs (Figure S1 and Figure S2, respectively). For
simplicity, mice containing the disrupted Erk2
flox/flox allele
henceforth will be referred to as Erk2
2/2 mice. Animal care and
experiments were conducted according to the guidelines estab-
lished by the Indiana University Animal Care and Use Committee
(IACUC). Age- and sex-matched WT, Erk1
2/2, and Erk2
2/2
mice were used for each experiment.
Bone marrow transplantation
2610
6 BMMNCs from WT, Erk1
2/2 and Erk2
2/2 mice were
injected intravenously into lethally-irradiated (1100 cGy) 8-week
old BoyJ mice [26]. Successful marrow reconstitution was
confirmed by flow cytometry of CD45.2 expression in peripheral
white blood cells, and stable Erk2 allele deletion was confirmed by
western blot. Bone mineral density (BMD) was measured six
months after bone marrow transplantation.
BMD quantification
Bone mineral density (BMD) was measured by dual-energy X-ray
absorptiometry (DEXA) with a Lunar Piximus densitometer (GE
Medical Systems, software version 1.4 Lunar) [27]. The mice were
anesthetized with avertin/tribromoethanol (0.25 mg/kg) and placed
into the scanner in the prone position with arms and legs extended.
The BMD of the leftfemoralmetaphysiswasmeasured bydefininga
regionofinterestof11pixels610pixelsproximaltothedistalgrowth
plate, a region containing high content of trabecular bone.
Micro computed tomography (mCT)
To evaluate trabecular microarchitecture in the distal femoral
metaphysis, fixed femurs (stored in 70% EtOH) were scanned using
a high-resolution desktop microcomputed tomography imaging
system (mCT-20; Scanco Medical AG, Basserdorf, Switzerland).
Scanning for the femur was started at 15% of the total femur length
measured from the tip of femoral condyle and extended proximally
for 200 slices with an increment of 9 mm, which were then
reconstructed, filtered (s=0.8 and support=1.0), and thresholded
(at 22% of the possible gray scale value) for analysis, as described
previously [28]. The trabecular region was outlined within the
trabecular compartment, excluding the cortical shell. Parameters of
microarchitecture for bone volume fraction (BV/TV, %), trabec-
ular number (Tb.N, mm
21), trabecular thickness (Tb.Th, mm), as
well as and trabecular separation (Tb.Sp, mm) were measured.
Clonogenic progenitor assays
Colony-forming unit-macrophage/monocyte (CFU-M) of
BMMNCs were assayed, as described previously [27]. Briefly,
2.5610
4 BMMNCs were seeded onto a 35-mm gridded dish
containing methylcellulose supplemented with murine recombi-
nant macrophage-colony stimulating factor (M-CSF, 30 ng/mL)
and murine recombinant RANKL (20 ng/mL) for 7 days at 37uC
in a 5% CO2 incubator. Colonies were scored using an inverted
light microscope. All cytokines were purchased from PeproTech
(Rocky Hills, NC).
Generation of murine osteoclasts and tartrate resistant
acid phosphatase (TRACP) staining
Mouse osteoclasts were obtained in vitro using BMMNCs, as
described previously [27]. BMMNCs from 8-week old WT,
Erk1
2/2, and Erk2
2/2 mice were isolated by long bone marrow
flush and Ficoll density gradient isolation and cultured in a-MEM
supplemented with 10% fetal bovine serum (FBS, Sigma), 30 ng/
mL M-CSF and 20 ng/mL RANKL for 3 days. On day 4, cell
culture media was switched to a-MEM supplemented with 10%
FBS, M-CSF (30 ng/mL), and 60 ng/mL RANKL for another 3
days. To identify osteoclasts after this culture period, adherent cells
were fixed with a solution containing 25 mL citrate solution,
65 mL acetone, and 8 mL of 3.7% formaldehyde, and stained for
TRACP. Osteoclasts were visualized with a Nikon TE2000-S
microscope (Nikon Inc., Melville, NY). Images were taken by a
QImaging camera and QCapture-Pro software (Fryer Company
Inc., Cincinnati, OH). Multinucleated TRACP
+ cells containing
more than three nuclei were scored as mature osteoclasts. The
area of multinucleated, TRACP
+ osteoclasts and the number of
nuclei per osteoclast were calculated using MetaMorph Offline
software (Molecular Devices, Inc. Sunnyvale, CA).
Bone resorption assay
Osteoclasts were dissociated from tissue culture plates using
0.5% Trypsin-EDTA. Single-cell suspensions of purified osteo-
clasts were seeded at a density of 1610
4/well on dentine slices
(ALPCO Diagnostic, Windham, NH) pre-wetted with a-MEM for
2 hours and then incubated at 37uC/5% CO2 in the presence of
30 ng/mL M-CSF and 60 ng/mL RANKL, as previously
described [27]. Following 7 days of culture, the slices were rinsed
with PBS, immersed overnight in 1 M ammonium hydroxide, and
stained with a 1% toluidine blue/0.5% sodium tetraborate
solution. At the same time, cells on dentine slices in the
independent cultures were fixed and stained with TRACP for
osteoclast counting. Microphotographs were taken under a
reflective light microscopy at a 1006 magnification, and the
resorptive areas or ‘‘pits’’ in low-power field were analyzed by the
MetaMorph Offline software. Six fields per condition were scored.
Migration assay
Migration of preosteoclasts was evaluated with a transwell assay,
as described previously [27]. Equivalent numbers of cells were
loaded onto the upper chamber of an 8 mm polycarbonate
transwell (Corning Inc., Lowell, MA) coated with vitronectin
(Takara, Japan) for 15 hours in a humidified incubator at 37uC/
5% CO2. The lower chamber contained a-MEM supplemented
with 0.1% bovine serum albumin and M-CSF (30 ng/mL). Cells
that migrated to the bottom chamber were stained with crystal
violet and the number of migrated cells per field was counted. Six
fields per condition were counted.
Preosteoclast adhesion assay
A single-cell suspension of osteoclast precursors (1610
4 cells/
well) were placed into 96-well plates pre-coated with vitronectin as
previously described [29]. After 30 minutes of incubation,
Erk1, Erk2, and Osteoclasts
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adherent cells were fixed and counted.
Western blotting analysis
Western blot using phospho-specific antibodies was conducted
to determine the phosphorylation levels of Erk1/2 and p90
rsk, (Cell
Signaling, Danvers, MA) in preosteoclasts [29]. Phosphorylation
levels were compared to total-ß-actin levels (Cell Signaling).
Briefly, cells were deprived of growth factors for 12 hours in a-
MEM supplemented with 0.5% BSA, stimulated with or without
30 ng/mL M-CSF for 5 minutes and lysed in ProteoJET lysis
buffer (Fermentas, Glen Burnie, MD) supplemented with Com-
plete Mini protease inhibitor cocktail (Roche, Indianapolis, IN).
The intensity of the bands was measured with Fluorchem Software
(Cell Biosciences, Inc., Santa Clara, CA) and standardized with
beta-actin for arbitrary intensity comparison.
Detection of C-terminal telopeptide of type I collagen
(CTX) in plasma
Blood was collected from the retrobulbar venous plexus and
kept in EDTA coated tubes, which were immediately cooled on ice
and centrifuged within 30 min. Plasma samples were stored at
280uC before being tested. All samples were analyzed in the same
experiment. CTX concentrations were determined using a
commercial enzyme immunoassay kit (Ratlaps
TM EIA, Immuno-
diagnostic systems Inc., Fountain Hills, AZ).
Histomorphometric measurements
Upon sacrifice, femurs were harvested for histomorphometric
analyses. The isolated bones were fixed in 10% neutral buffered
formalin for 48 hours, dehydrated in graded ethanols, and
embedded undecalcified in methyl methacrylate. Sagittal sections
(5 mm thick) were cut from the middle of the femur. TRACP
staining was performed using a leukocyte acid phosphatase kit
(Sigma Diagnostics, St. Louis, Missouri) and McNeal Staining
was performed using McNeal’s Tetrachrome kit (Polysciences,
Warrington, Pennsylvania), both according to manufacturers’
protocols. One section per femur was viewed at 1006
magnification on a Leitz DMRXE microscope (Leica Mikrosko-
pie und System GmbH, Wetzlar, Germany) and the image
captured using a QImaging camera and QCapture-Pro software
(Fryer Company Inc., Cincinnati, OH). The measurement area
for the metaphysis was determined by a region beginning 0.5 mm
proximal to the midpoint of the growth plate, non-inclusive of
cortical bone, and extending proximally for a total area of
approximately 2.8 mm
2.
Alpha V (av) integrin detection by flow cytometry
Expression of av integrin was assessed by flow cytometry.
Preosteoclasts were blocked using CD16/32 (BD Biosciences),
washed and incubated with PE-linked anti-CD51 (av integrin)
antibody (BD Biosciences) for 60 min at 4uC. After three further
washing steps, CD51 expression was measured using a FACS-
Calibur
TM flow cytometer (Becton-Dickinson, San Jose, USA).
Data were analyzed with FlowJo Software (version 7.6, TreeStar
Inc.).
Statistical analyses
Unpaired or paired student’s t-tests or ANOVA with appropri-
ate post hoc corrections were used, as indicated, to evaluate
differences among genotypic groups. P values less than 0.05 were
considered significant. Statistical analyses were performed with
Prism 5.0 software (GraphPad, La Jolla, CA).
Results
Deletion of Erk1 or Erk2 in BMMNCs and cultured
osteoclasts
PCR was conducted to assay the presence of the Erk1 null allele
(Erk1
2/2), Mx1Cre transgene, and flanking loxP (Erk2
flox/flox) alleles.
Figure S1 depicts the genomic PCR analysis for homozygous null
Erk1 (600 bp) and homozygous floxed Erk2 (432 bp).To induce
Cre expression and genetic disruption of Erk2, mice were treated
with polyIC, as described in the Materials and Methods. Western
blot analysis demonstrated undetectable Erk1 or Erk2 in protein
isolates from BMMNCs extracted from genomic-verified Erk1
2/2
or Mx1Cre
+ Erk2
flox/flox mutant mice (Figure S2, top panels).
Likewise, western blot of protein from cultured osteoclasts
demonstrated no detectable Erk1 or Erk2 protein (Figure S2
lower panels). For simplicity throughout, we refer to the genotypes
of BMMNCs and osteoclasts derived from polyIC-treated Mx1Cre
+
Erk2
flox/flox mice as Erk2
2/2.
Decreased multinucleated osteoclast formation from
Erk1
2/2 BMMNCs
To evaluate the consequence of Erk1 or Erk2disruptionin osteoclast
differentiation, we cultured osteoclasts from BMMNCs in M-CSF-
and RANKL-supplemented a-MEM, followed by TRACP staining to
evaluate cellular morphology. Compared with wildtype (WT) cultures,
Erk1
2/2 BMMNCs demonstrated significantly decreased osteoclast-
forming areas, as shown qualitatively and quantitatively in Figure 1A
and 1B, respectively. In addition, the average number of nuclei per
osteoclast was significantly less in Erk1
2/2cultures than that in WT or
Erk2
2/2 cultures (Figure 1C). Although we found no difference in the
size of osteoclasts between Erk2
2/2 and WT cultures, the number of
nuclei of Erk2
2/2 osteoclasts were slightly decreased as compared to
WT osteoclasts. Erk1
2/2 cells display impaired osteoclast differenti-
ation while Erk2 level should remain at least as WT cell level. It is
possible that ERK2 expression in osteoclasts is not high enough to
compensate for the loss of ERK1.
Genetic deletion of Erk1 impairs osteoclast migration and
bone resorption
Osteoclast bone resorptive capacity requires that osteoclast
progenitor cells (preosteoclasts) migrate across the bone surface.
To evaluate whether genetic disruption of Erk1 or Erk2 affects
preosteoclast migration in vitro, we assessed transwell migration of
preosteoclasts in response to recombinant M-CSF, a chemotactic
signal for monocytic cells [27,29]. Erk1
2/2 preosteoclasts migrated
at a lower number than both WT and Erk2
2/2 preosteoclasts in
response to M-CSF, as shown by representative microphotograph
of migrated cells and by quantification (Figure 2A). By contrast,
Erk2
2/2 preosteoclasts did not demonstrate alterations in M-CSF-
induced migratory capacity.
The initiation of osteoclastic bone resorption depends on
osteoclasts’ ability to bind to the bone surface through the
interaction of cell surface receptors, such as the avb3 integrin, with
extracellular bone proteins [27,30,31,32]. We examined whether
deficiency of Erk1 or Erk2 affects avb3- and M-CSF-mediated
preosteoclast adhesion. We found that fewer Erk1
2/2 preosteo-
clasts adhered to vitronectin during stimulation with M-CSF
(Figure 2B), while the expression of integrin av (CD51) was similar
between the different genotypes (data not shown). We found no
difference between WT and Erk2
2/2 osteoclasts in their capacity
to adhere to vitronectin in cell culture.
To functionally assess the consequence of Erk1 or Erk2
disruption on osteoclast bone lytic activity, we cultured osteoclasts
Erk1, Erk2, and Osteoclasts
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formed by osteoclast resorptive activity, as previously described
[27,29]. Representative microphotographs of bone resorption are
shown (Figure 2C). The quantitative data represents the total
resorptive area (Figure 2C, upper panel). The resorptive area per
osteoclast is shown quantitatively (Figure 2D). Erk1
2/2 osteoclast
culture demonstrated a three-fold reduction in resorbed area and
the Erk2
2/2 osteoclast culture demonstrated an approximate two-
fold reduction, as compared to the WT osteoclast culture.
Collectively, these data indicate that Erk1 positively regulates
osteoclast differentiation and M-CSF-mediated migration and pit
formation. Deletion of Erk2 also reduces osteoclast nucleation and
bone resorptive activity (albeit less substantially than Erk1). Erk1
2/2
cultures show stronger phenotypic changes although Erk2 exists.
This may be explained by ERK2 expression in osteoclasts is not
high enough to compensate for the loss of ERK1. Nevertheless,
our cell culture data suggests important and preponderant
contributions of Erk1 toward osteoclast differentiation and
function.
Genetic deletion of Erk1 in osteoclasts reduces total
kinase activity
To examine biochemical alterations in the MAPK pathway in
the context of Erk1 or Erk2 disruption, we stimulated cultured
preosteoclasts with M-CSF (30 ng/mL), lysed the cells, and
extracted protein for western blot. We assessed total and
phosphorylated levels of Erk1, Erk2, and p90
rsk, a downstream
Erk1/2 effector. Following M-CSF stimulation, Erk1 phosphory-
lation increased dramatically in WT and Erk2
2/2 cells, while no
pErk1 was detected in Erk1
2/2 cells (Figure 3A). Interestingly, a
slight, perhaps compensatory, increase in pErk1 was observed in
Erk2
2/2 cells, as compared to WT. Similarly, we observed a
moderate increase in pErk2 levels in M-CSF-stimulated Erk1
2/2
preosteoclasts, as compared to WT cells. As expected, no pErk2
was observed in Erk2
2/2 cells.
We also found a substantial reduction in phospho-p90
rsk in M-
CSF-stimulated Erk1
2/2 preosteoclasts, as compared to stimulated
WT and Erk2
2/2 cells (Figure 3B). Since PI3-K has been shown to
regulate osteoclast development [33], we also examined phos-
phorylation of Akt in the cultured preosteoclasts. Similar levels of
Akt phosphorylation were observed among WT, Erk1
2/2, and
Erk2
2/2 preosteoclasts (data not shown), suggesting that the
functional aberrancies observed in Erk1-deficient osteoclasts are
Akt independent. Quantitative analysis of the western blot result is
shown in Figure S4.
Genetic deletion of Erk1 reduces osteoclast progenitors
Since osteoclasts are tissue-specific progeny of the monocyte/
macrophage lineage, we quantitatively evaluated the number of
macrophage and osteoclast progenitors per femur in Erk1
2/2,
Erk2
2/2, and WT mice using established clonogenic assays [27].
Following culture in semisolid media supplemented with osteo-
clast-promoting cytokines (i.e. M-CSF, RANKL), the number of
osteoclast and macrophage progenitor colonies were scored.
Erk1
2/2 BMMNCs developed approximately one-fourth to one-
third fewer macrophage colonies as compared to the number of
colonies formed from Erk2
2/2 and WT BMMNCs (Figure 4A).
Although the osteoclast progenitors are decreased in Erk2
2/2 also,
the result showed that Erk1 plays a more vital role than Erk2 in
osteoclastogenesis. Of note, there was no significant difference in
Figure 1. Genetic deletion of Erk1 hinders osteoclast development. (A) Representative microphotograph of osteoclast formation of the
indicated genotypes generated in vitro following culture in a-MEM, 10% FBS, M-CSF 30 ng/mL and RANKL 60 ng/mL for 6 days. Osteoclasts were
identified by TRACP staining. (B) Quantitative analysis of the area of osteoclasts is shown. *P,0.01 for Erk1
2/2 vs. WT and Erk2
2/2 by ANOVA
followed by post-hoc t-tests. (C) Quantitative analysis of the number of nuclei per osteoclast is shown. Data represents Mean 6 SEM of six fields per
condition in triplicates. Experiments were conducted on three independent occasions with similar results. *P,0.01 for Erk1
2/2 vs. WT and Erk2
2/2 vs.
WT as assessed by ANOVA followed by post-hoc t-tests.
doi:10.1371/journal.pone.0024780.g001
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2/2, Erk2
2/2, and WT
mice (data not shown), indicating a primary reduction in the
frequency of monocyte/osteoclast progenitor cells in Erk1
2/2
bone marrow.
Reduced TRACP
+ osteoclast development in Erk1
2/2
mice
Given the impaired osteoclast differentiation in vitro and reduced
number of osteoclast progenitors in Erk1
2/2 bone marrow, we
next assayed the number of mature osteoclasts in Erk1
2/2 mice in
vivo. The femurs of 8-week old syngeneic WT, Erk1
2/2 and
Erk2
2/2 mice were fixed and embedded in methyl methacrylate,
and histological sections from the distal metaphysis were stained
with the osteoclast enzyme TRACP. Compared to WT mice, the
TRACP
+ area per low power field (1006 magnification) of
trabecular surface in Erk1
2/2 mice was decreased as qualitatively
and quantitatively shown in Figure 4B and Figure 4C, respectively.
To determine if deletion of Erk1 additionally alters osteoblast
formation, McNeal staining was performed on the methyl
methacrylate processed histological sections, revealing no signifi-
cant change in osteoblast numbers between WT, Erk1
2/2, and
Erk2
2/2 bone sections (Figure S3).
Reduced C-terminal telopeptide of type I collagen (CTX)
in Erk1
2/2 mice
Type I Collagen, which constitutes more than 90% of the organic
matrix of bone, can be degraded and released during osteoclastic
bone resorption. Thus, the level of CTX production in plasma is a
sensitive marker of bone loss [34]. The level of CTX production in
plasma was substantially reduced in Erk1
2/2 mice as compared
with that in WT and Erk2
2/2 mice (Figure 4D), suggesting a
reduced osteoclast bone resorptive activity in Erk1
2/2 mice in vivo.
Figure 2. Effect of Erk1 deletion on osteoclast haptotaxis, adhesion, and bone resorption in response to M-CSF. (A) Haptotaxis of
preosteoclasts from WT, Erk1
2/2, Erk2
2/2 cultures in response to M-CSF. Representative microphotographs of low power field (1006magnifications)
from 1 of 3 experiments are shown. Quantitative evaluation of migration in response to M-CSF was performed. Result represents the mean 6 SEM of
six fields per condition in triplicates. Three independent experiments were conducted with similar results. *P,0.01 by ANOVA. (B) Quantitative
evaluation of M-CSF mediated preosteoclast adhesion (30 minutes) to aVb3 is shown. Data represents mean 6 SEM of six fields per condition of
triplicates. Representative microphotographs (1006 magnification) are shown. *P,0.01 by ANOVA followed by post-hoc t-tests. Experiment
conducted on three independent occasions with similar results. (C) Representative microphotographs of the bone resorption on dentine slices,
referred to as ‘pits’, are shown. Bar graph indicates the average of ‘‘pit’’ area per dentine slice. Data represents mean+standard error of the mean
(SEM). *P,0.01 for Erk1
2/2 vs. WT, **P,0.05 for Erk2
2/2 vs. WT and Erk1
2/2 as assessed by ANOVA followed by post-hoc t-tests. (D) Quantitative
analysis of bone resorption following culture of osteoclasts on dentine slices. The area of the resorbed regions per osteoclasts was quantified. Data
represents one of three independent experiments with similar results. *P,0.01 for Erk1
2/2 vs. WT, **P,0.05 for Erk2
2/2 vs. WT and Erk1
2/2 as
assessed by ANOVA followed by post-hoc t-tests.
doi:10.1371/journal.pone.0024780.g002
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2/2 mice and
Erk1
2/2 bone marrow mononuclear cell transplanted
recipients
Given that alteration in osteoclast bone resorptive activity
affects bone structure, we hypothesized that Erk1
2/2 mice
would demonstrate increased bone mineral density (BMD). To
test this hypothesis, we acquired BMD data using dual-energy
X-ray absorptiometry (DEXA) with a Lunar Piximus densitom-
eter. We specifically analyzed a region of interest with a high
content of trabecular bone, located proximal to the distal growth
plate of the left femur of each mouse. Erk1
2/2 male mice
demonstrated increased BMD, as measured monthly after birth
(Figure 5A). Erk1
2/2 female mice also displayed increased BMD
as compared to WT littermates (Figure 5B), though the
difference was milder than in the male mice. However, the
cause of the different BMD between male and female mice
remains unclear.
To compare the long bone mass between the WT and Erk1
2/2
mice, micro-computed tomography (mCT) was utilized to examine
the bone volume and architecture. Erk1
2/2 mice exhibited an
,80% increase (**P,0.05) in trabecular bone volume fraction
(BV/TV), (Figure 5C and 5D); an ,15% increase (**P,0.05) in
trabecular thickness, an ,50% increase (**P,0.05) in trabecular
number, and an ,30% decrease (**P,0.05) in trabecular
separation, as compared to the WT controls (Figure S6A–C).
This increased bone volume in Erk1
2/2 mice is consistent with the
increase of BMD in Erk1
2/2 mice.
Based on our tissue culture and in vivo findings, we hypothesized
that aberrant formation and function of Erk1
2/2 osteoclasts
directly results in increased BMD. To test this hypothesis, we
performed long-term transplantation [26] of BMMNCs from WT,
Erk1
2/2 and Erk2
2/2 mice into lethally-irradiated WT BoyJ
recipient mice, thus isolating our analysis to cells derived from the
donor hematopoietic cells. For complete reconstitution of
hematopoietic cells, we waited six months after the transplantation
to confirm successful reconstitution of hematopoietic stem cells
and Erk2 allele deletion by flow cytometry-based detection of
CD45.2 expression (data not shown) and by western blot of
peripheral blood (Figure S5), respectively. We then measured
BMD in the recipient mice, finding that Erk1
2/2 bone marrow
reconstitution produced increased BMD as compared to WT
recipients (Figure 6), while transplantation of Erk2
2/2 BMMNCs
did not alter BMD as compared to WT recipients. These data
imply a marrow-autonomous role for Erk1 in regulating osteoclast
development and bone resorptive activity in vivo.
Discussion
Alterations of the Ras/MAPK pathway have been observed in
disease models of Paget’s bone disease, bone metastasis, and
Neurofibromatosis type 1 (NF1) [35,36,37,38]. Moreover, con-
genital disorders including Noonan syndrome, Noonan-like/
multiple giant cell lesion syndrome, NF1, LEOPARD syndrome,
Costello syndrome, and Cardio-facio-cutaneous syndrome carry
germline mutations that variously affect genes within the MAPK
signaling cascades [39]. These studies broadly implicate deregu-
lation of Ras signals in skeletal pathologies. However, the
interaction between and contribution of individual cell lineages
(e.g. osteoblasts, osteoclasts, mesenchymal stromal cells) to specific
pathologies, as well as their potential dependence on a specific Erk
isoform, require further delineation.
Figure 3. Effect of Erk1 genetic deletion on MAPK activation in preosteoclasts. Phosphorylation of Erk1/2 (Figure 3A) and p90RSK (Figure 3B)
in preosteoclasts of WT, Erk1
2/2 and Erk2
2/2 mice was measured at the indicated times following stimulation with M-SCF. Representative blots are
shown.
doi:10.1371/journal.pone.0024780.g003
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reduces osteoclast development and belt formation [29]. Since
PD98059 inhibits phosphorylation of both Erk1 and Erk2, and
perhaps exhibits a high degree of non-selectivity at its applied
concentration, we were unable to delineate if Erk1, Erk2, both, or,
potentially, neither isoform modulates osteoclast differentiation.
Here, we show that genetic disruption of Erk1 versus Erk2
preferentially impairs osteoclast formation and function in vitro and
in vivo. Important to note, this phenotype arises in a marrow-
autonomous manner, implicating Erk1’s importance to the
marrow-derived osteoclast and its regulation of normal bone
physiology. Although we show that Erk2 cannot compensate,
either functionally or biochemically, for loss of Erk1 in the
osteoclast, we still suspect that Erk2 can positively contribute to
osteoclastogenesis and osteoclast function. Supporting this notion,
we have found that Erk1/2 dual disruption ablates early
myelopoiesis and precludes the study of osteoclastogenesis, a
phenotype which will be reported in detail elsewhere. By contrast,
Erk1 appears largely capable of compensating for Erk2 disruption
in the observed biochemical and functional phenotypes. Thus, we
have concluded that Erk1 plays the preponderant role in
regulating osteoclastogenesis and osteoclast function. However, it
remains unknown whether this phenotype results from isoform
functional specificity or solely from osteoclast-intrinsic dependence
on increased Erk1 expression and/or activation.
Biochemical, pharmacological, and genetic models have
broadly implicated ERK1/2 activity in proliferation, survival,
migration, and protein synthesis in diverse cell types (reviewed in
[40]). However, lineage- and isoform-specific functions are less
known, and genetic murine studies have been limited, thus far
demonstrating Erk1-specific requirements for thymocyte develop-
ment [18], erythropoiesis [41], adipogenesis [19], and skin tumor
development [17]. Other studies have suggested a negative
regulatory role for Erk1, whereby Erk1 disruption enhances
fibroblast and neuron function by dis-inhibiting Mek-Erk2 signals
[42,43]. These data suggest the preponderance of Erk2 over Erk1
function in these cell types. Accordingly, Erk2 disruption is
embryonically lethal [44] while, grossly, Erk1
2/2 mice demon-
strate no profound phenotypes [18]. However, as reported
elsewhere and as we show here for the osteoclast, homeostatic
processes in particular organ systems may depend upon Erk1, and
generalizations as to Erk1 versus Erk2’s functional importance
should not be derived from observations in one cell type. Our
results showed that Ekr1 had higher expression level than Erk2 in
preosteoclasts; it is most likely that Erk1 has higher affinity than
Erk2 does for the antibody.
Figure 4. Genetic deletion of Erk1 affects osteoclast progenitor frequency and osteoclast formation in vivo. (A) BMMNCs of the
indicated genotypes were cultured in agar-based media containing M-CSF (30 ng/mL) and RANKL (20 ng/mL) for 7 days and CFU-macrophage (M)
were counted based on morphology. Y-axis indicated CFU-M number per femur. Data represents mean 6 SEM of triplicate cultures. *P,0.01 for
Erk1
2/2 vs. WT, **P,0.05 for Erk2
2/2 vs. WT and Erk1
2/2, as evaluated by ANOVA followed by post-hoc t-tests. Experiments were conducted on three
independent occasions with similar results. (B) Representative microphotographs (406, 1006 magnification) of WT, Erk1
2/2 and Erk2
2/2 distal
femoral metaphyses following TRACP staining. Arrows indicate selected osteoclasts. Scale bar=100 mm. (C) Data represent the mean 6 SEM of 5
independent experiments. Ten high-power fields per experimental mouse were scored. *P,0.01 for Erk1
2/2 vs. WT and Erk2
2/2, as analyzed by
ANOVA followed by post-hoc t-tests. (D) Detection of CTX in plasma of WT, Erk1
2/2 and Erk2
2/2 mice (N=4–6 mice in each group).*P,0.05 for Erk1
2/2
vs. WT, as analyzed by ANOVA followed by post-hoc t-tests.
doi:10.1371/journal.pone.0024780.g004
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vivo will produce crucial insights into the subtleties of MAPK
signaling, thus informing therapeutic strategies. Accordingly, ERK
isoform-specific chemical inhibition may prove pivotal to targeted
therapy. Though bisphosphonates have been the cornerstone of
osteoporosis therapy since the 1960’s, recent work has focused on
more selective compounds [45]. Molecular targets to Ras itself,
such as farnesyl transferase inhibitors, have been disappointing, as
K-ras and N-ras, the isoforms prevalent in myeloid lineages, do
not depend on farnesylation. Because disruption of Erk1 dampens
osteoclast function to a degree sufficient to increase bone mineral
density in vivo, an Erk1-targeted chemical kinase inhibitor may be
an effective therapeutic agent for the diminished bone mineral
density found in multiple skeletal pathologies, including hormonal
loss-dependent osteoporosis. This strategy may selectively modu-
late osteoclast function while producing fewer off-target and
detrimental effects potentially associated with dual Erk1/2
inhibition. Of note, a recent crystal structure of human ERK1
revealed substantial differences in D-motif and backside binding
sites, as compared to ERK2, indicating the feasibility of a selective
ERK1 inhibitory agent [46].
In conclusion, osteoclastogenesis and osteoclast functions depend
upon Erk1 to a greater degree than Erk2, and singular genetic
inhibition of Erk1 mitigates osteoclast function in vitro and in vivo.
This loss-of-function phenotype appears to proceed in a marrow
autonomous manner, thus implicating a primary defect within the
Erk1-disrupted osteoclast. These results uniquely demonstrate a
positiveregulatorrole forErk1whilesuggestingthepotentialforErk
isoform-targeted therapy of osteoporotic conditions.
Figure 5. Erk1
2/2 mice have increased BMD and BV/TV. BMD of age and sex matched Erk1
2/2 and WT mice was measured from birth to 7
months of age. The BMD of male (A) and female (B) WT and Erk1
2/2 mice is shown (N=5 mice in each group). (C) Representative mCT reconstructions
of WT and Erk1
2/2 femurs are shown. Scale bar=1 mm. (D) Quantitative data comparing the left femur BV/TV between WT and Erk1
2/2 mice.
doi:10.1371/journal.pone.0024780.g005
Figure 6. Transplantation of Erk1
2/2 bone marrow increases
BMD in WT recipients. Six months after transplantation with WT,
Erk1
2/2 or Erk2
2/2BMMNCs into WT recipient mice, BMD was measured
(N=5 mice in each group). **P,0.05 for Erk1
2/2 vs. WT recipients, as
analyzed by ANOVA followed with post-hoc t-tests.
doi:10.1371/journal.pone.0024780.g006
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Figure S1 Genotypic analysis. PCR was performed to confirm
the genotype of WT (lane 1), Erk1
2/2 (lane 2) and Mx1Cre
+ Erk2
fl/fl
(lane 3) mice.
(TIF)
Figure S2 Western Blot. Representative western blot of three
independent experiments shows the total protein level of Erk1 or
Erk2 in bone marrow mononuclear cells (BMMNCs) and
osteoclast. b-actin was utilized as a loading control.
(TIF)
Figure S3 (A) Representative microphotographs (1006 magni-
fication) of WT, Erk1
2/2 and Erk2
2/2 distal femoral metaphyses
following McNeal Staining. Arrows indicate selected osteoblasts.
(B) Data represent the mean 6 SEM of 5 independent
experiments. Six high-power fields per experimental mouse were
scored. Scale bar=50 mm.
(TIF)
Figure S4 Quantitative evaluation of Erk1 phosphorylation over
ß-actin level of Figure 3. (A), Erk2 phosphorylation (B), and
phosphorylation of p90RSK (C) in WT, Erk1
2/2 and Erk2
2/2
preosteoclasts is shown.
(TIF)
Figure S5 Western blot shows the protein levels of Erk1 and
Erk2 in peripheral blood of the WT and Erk1
2/2 transplanted
WT recipients. Scale bar= 1 mm.
(TIF)
Figure S6 Quantitative data comparing the left femur Tb.Th,
Tb.N and Tb.Sep between WT and Erk1
2/2 mice (N=5 in each
group). **P,0.05 for Erk1
2/2 vs. WT mice.
(TIF)
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